

*Radiochirurgia adiuvante dopo chirurgia  
“conservativa”: un approccio efficace per i  
tumori cerebrali complessi*

*G Minniti*

*Radiation Oncology, Sant’Andrea Hospital  
and Neuromed Institute  
University of Rome Sapienza*






SAPIENZA  
UNIVERSITÀ DI ROMA




*AIRO, Rome 18-11-2012 BrainLab Symposium*

# Skull base tumors



# Skull base surgery



- ✓ *Surgical resection has long been standard care for cranial base tumors.*
- ✓ *While extensive surgery is curative in selected patients, because of the complexity of anatomy of this region postoperative morbidity remains high (up to 50%).*
- ✓ *Subtotal or partial resection is associated with less morbidity, however with a high tendency for regrowth.*
- ✓ *Local control following incomplete excision of a benign skull base tumor can be improved with SRT with a reported 5-year progression-free survival in the region of 80-100%*

# SRS/SRT for skull base tumors

- *Pituitary adenomas*
- 90-95% at 5 years / 90-100% at 5 years
- *Meningiomas*
- 90-100% at 5 years / 90-100% at 5 years
- *Acoustic neuromas*
- 90-100% at 5 years / 90-100% at 5 years
- *Craniopharyngiomas*
- 50-80% at 5 years / 90-100% at 5 years





Minniti et al, Rev Endocr Metab Disord. 2009,  
Minniti et al , Rad Oncol 2009 and 2011,  
Minniti et al , Neurosurgical Rev 2009,



# *“conservative” surgery followed by adjuvant SRT/SRS in 64 patients with skull base tumors*

- *18 meningiomas*
- *13 acoustic neuromas*
- *22 pituitary adenomas*
- *11 craniopharyngiomas*



# *Combined approaches to skull base tumors*



*36 TSS/EES*



*28 open surgery*


# Characteristics of 64 patients with large skull base tumors treated with surgery and stereotactic irradiation



<b>Sex</b>	24M\40 F
<b>Median age (range)</b>	56 yrs (34-74)
<b>KPS</b>	
70-80	34
90-100	30
<b>Surgery</b>	
TSS/EES	36
open	28
<b>Neurologic deficits</b>	28
<b>Hypopituitarism</b>	21
<b>Radiation technique</b>	
SRS	25
SRT	39
<b>Gross tumour volume (GTV)</b>	
Median	7.4 cm <sup>3</sup>
Range	0.4 – 34.9 cm <sup>3</sup>
<b>Planning target volume (PTV)</b>	
Median	10.6 cm <sup>3</sup>
Range	1.5 –62.7 cm <sup>3</sup>





52



12







# Acoustic neuroma







# SRS for residual acoustic neuroma




POST SRS (1 year)





# Acoustic neuroma





Pre-operative









*Surgery with neurophysiologic monitoring of cranial nerves, motor and sensitive paths*




Post-operative



# SRT for residual acoustic neuroma




100.0 % = 5.00 Gy




POST SRT (18 months)



# Large skull base meningioma





Pre-surgery





Post-surgery



Pre-FSRT





Post-FSRT  
5450 RM ENCEFALO C




# Large skull base meningioma











Pre-surgery




Post-surgery  
Intraoperative MRI








100.0 % = 1.67 Gy


# Surgery followed by SRS for an ACTH-secreting pituitary adenoma



Pre-surgery







Post-surgery









# NF pituitary adenoma






# craniopharyngioma





Endoscopic surgery



Post-surgery





3-years Post-SRT





Pre-surgery

*craniopharyngioma*




*intraoperative-MRI*


*Endoscopic surgery*



*Postoperative SRT*




*Pre-operative*



*2-years POST FSRT*

*Tumor control in 64 patients with skull base tumors  
Treated with surgery followed by SRS/SRT*



# *Neurological function*

- *Neurological deficits were present in 28 patients before surgery and in 24 patients before irradiation*
- *At a median f-up of 41 months, 25% of patients had a clinical improvement of neurological deficits after SRT/SRT*
- *Vision improved in 4 patients and cranial nerve function in 2 patients*
- *Three patients deteriorated without evidence of tumor progression on imaging. One patient had a slight worsening of vision and two progressive hearing loss*



## *late toxicity*

- *A development of new or worsening of pre-existing hypopituitarism occurred in 15% of patients after a median follow-up of 38 months, requiring hormone replacement therapy*
- *No clinically apparent neurocognitive dysfunction (Grade II RTOG memory impairment) was reported.*
- *No radiation necrosis, cerebrovascular accidents and second tumors were reported.*



## *Surgical morbidity in 64 patients with skull base tumors*

- ✓ *Hipopituitarism* 3
- ✓ *CSF leak* 3
- ✓ *Cranial deficits* 3
- ✓ *Haemorrhaghe* 2



# Conclusions

- *Planned pre-operative limited resection followed by SRT/SRS (as part of a combined strategy employed in our institution) represents a suitable option in patients with skull base tumors which is associated with high local control and preservation of neurologic function*
- *SRS is usually employed only for small (< 2.5-3 cm) lesions at least 3 mm away from the optic pathway and not involving large parts of the brainstem (if doses > 12 Gy are used).*





*...thank you for your attention*



SAPIENZA  
UNIVERSITÀ DI ROMA

